Yuko Kanbayashi - Publications

Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study.

Journal: Future oncology (London, England)

Published: March 23, 2026

Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 24, 2025

Cardiac adverse events associated with axitinib: A real-world pharmacovigilance study based on the Japanese adverse drug event report database.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: September 25, 2025

Disproportionality Analysis of Gastrointestinal Adverse Events Associated With Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report database.

Journal: In vivo (Athens, Greece)

Published: July 19, 2025

Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database.

Journal: Clinical drug investigation

Published: July 04, 2025

Disproportionality analysis of cardiac adverse events associated with sorafenib using Spontaneous Reporting Database in Japanese.

Journal: Die Pharmazie

Published: April 10, 2025

Efficacy of compression therapy for prevention of peripheral neuropathy caused by taxane-based chemotherapy: a single-center retrospective observational study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: January 27, 2025

Factors Contributing to Blood Glucose Elevation Associated With Olanzapine Used as an Antiemetic During Cancer Chemotherapy.

Journal: In vivo (Athens, Greece)

Published: November 10, 2024

Evaluation of Lung Adverse Events Associated With Lenvatinib: A Post-marketing Surveillance Study.

Journal: In vivo (Athens, Greece)

Published: September 07, 2024

Evaluation of Times-to-onset and Outcomes of Lung Adverse Events Associated With Sorafenib Using JADER.

Journal: In vivo (Athens, Greece)

Published: August 30, 2024

Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database.

Journal: British journal of clinical pharmacology

Published: June 09, 2024

Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients.

Journal: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Published: November 23, 2023